WATCHLONGEVITY

Monday, May 4, 2026

Amgen launches late-stage obesity trial in patients who switch from rival drugs
DEVELOPING
MAJOR78
CLINICAL TRIALLimited grounding

Amgen launches late-stage obesity trial in patients who switch from rival drugs

Amgen is testing its obesity drug MariTide in a new late-stage trial that includes patients switching from rival weight-loss drugs made by Eli Lilly and Novo Nordisk. The company is also launching two other large trials to gather more evidence that MariTide works.

Analysis

Amgen's switch-trial design directly targets Lilly and Novo patients, signaling MariTide is being positioned as a second-line option rather than first-line challenger.

  • Amgen launched a late-stage MariTide trial including patients switching from Lilly and Novo drugs
  • Two additional large MariTide trials are also being launched
  • Trials aim to gather more evidence that MariTide works
$AMGN$LLY$NVO
MariTideAmgenEli LillyNovo Nordisk
Endpoints News2d
Read
NOTABLE62
COMMERCIALLimited grounding

Biopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord Pharma

Novo Nordisk rebranded its oral semaglutide pill Rybelsus under the Ozempic name, aligning the product with its popular injection brand. Amgen reduced the size of its drug development pipeline.

Analysis

Novo leveraging the Ozempic brand on oral semaglutide signals a push to defend franchise equity as oral GLP-1 competition builds from Lilly and Pfizer.

  • Novo Nordisk rebranded oral semaglutide Rybelsus under the Ozempic name
  • Rebrand aligns the pill with Novo's injection franchise
  • Amgen reduced the size of its drug development pipeline
$NVO$AMGN
semaglutiderybelsusozempicNovo Nordisk
Semaglutide News1d
Read
NOTABLE60
COMMERCIALLimited grounding

Amgen positions MariTide as potential ‘best monthly’ obesity drug - BioSpace

Amgen is marketing MariTide, its once-monthly weight-loss drug, as potentially the best option in its drug class. The company is positioning it to compete with other monthly weight-loss medications on the market.

Analysis

Amgen is staking MariTide's commercial pitch on monthly dosing convenience, a differentiation play against weekly GLP-1 incumbents in the obesity market.

  • Amgen positioning MariTide as potential 'best monthly' obesity drug
  • MariTide is dosed once monthly
  • Amgen targeting competition with other monthly weight-loss medications
$AMGN
MariTideAmgen
BioSpace2d
Read